Boston Scientific (NYSE:BSX) today released data from the Lumina trial of its Precision Spectra spinal cord stimulator, touting a 70% improvement in back pain relief over its previous generation Precision Plus SCS.
Data from the Lumina study is being presented at the North American Neuromodulation Society’s annual meeting in Las Vegas this weekend, the company said.
“As the Lumina data show, the Boston Scientific Illumina 3D Algorithm allows me to treat low back pain more consistently and effectively than before. These data are impressive because they demonstrate sustained long term pain relief in an all-comers population; we did not exclude the type of challenging patients that physicians see every day,” Dr. James North of the Carolinas Pain Institute said in prepared remarks.
Marlborough, Mass.-based Boston Scientific said data from the study showed a significant decrease in average pain scores over a 2-year period and when the device was combined with the company’s CoverEdge surgical lead, demonstrated increased pain relief at 12 months. Boston Scientific gave credit for the increased pain relief to the device’s Illumina 3D neural targeting algorithm.
“We designed the Precision Spectra SCS System with the flexibility to deliver multiple waveforms using our powerful Illumina 3D Algorithm. These conclusive Lumina real-world clinical data demonstrate that the Precision Spectra SCS System is a significant advancement for improving the lives of patients with chronic pain,” neuromod prez Maulik Nanavaty said in a press release.
The test examined a total of 576 patients in 4 cohorts that compared its last generation SCS system to the Spectra, as well as the effect of its CoverEdge 32 surgical lead and a cohort in which disability was measured out to 12 months, the company said.
Boston Scientific said its Spectra-treated group demonstrated an average reduction from a baseline pain score of 7.17 to 2.94 at 24 months, and in a subset of severe patients with lower back pain, reported an average reduction from 8.6 to 2.98.
In the between-group study comparing the Spectra to the last-gen SCS, the company said it saw a 70% improvement in lower back pain scores between the 2 devices.
The cohort treated with its CoverEdge 32 surgical lead reported an average reduction from 7.8 to 2.6 at 12 months, and the disability-monitored group reported a reduction of more than 20 points over 12 months, as measured by the Oswestry Disability Index.
